Latest! China National Pharmaceuticals Group has submitted an application for a new crown vaccine;

According to the latest news from Xinhua Finance on November 25, Shi Yanyi, deputy general manager of China National Pharmaceutical Group Co., Ltd., said that China National Pharmaceutical Group has submitted an application for the listing of the new crown vaccine to the State Drug Administration.
Two production workshops have been established, annual output of up to 300 million doses It is reported that China National Pharmaceutical Group Co., Ltd. since the outbreak of the new crown, carried out two new crown vaccine research and development, one for inactivated vaccines, by its Wuhan Biological Products Institute, Beijing Biological Products Institute and the Chinese Academy of Sciences Wuhan Virus Institute, China Center for Disease Control and Prevention Virus Control Institute and China Food and Drug Research Institute in collaboration with research and development;
September 22nd, WHO's official Xuanguo Pharmaceutical Group's new crown vaccine has been shown to be effective.
earlier, Liu Jingxuan, chairman of the National Pharmaceutical Group, said that the domestic has begun the emergency use of the new crown inactivated vaccine, Chinese organisms have been prepared for large-scale production, to ensure adequate and safe vaccine supply.
In addition, the Beijing Institute of Biological Products and the Wuhan Institute of Biological Products, two inactivated vaccines owned by China Pharmaceutical Group, are now conducting phase III clinical trials in 10 countries, including the United Arab Emirates, Jordan, Peru, Argentina and Egypt, with a total of 60,000 inactivated vaccines.
It is worth mentioning that China Bio has built high-grade biosecurity production facilities at two biological products research institutes in Beijing and Wuhan, among which the Beijing Institute of Biological Research's new crown inactivated vaccine production plant received a regulatory license on August 5 this year, the world's first and largest new crown inactivated vaccine production workshop.
two vaccine production plants have a combined annual production capacity of 300 million doses.
the start of a potential vaccine price war, the pricing of national drugs is controversial Recently, a number of vaccines announced good news, Pfizer and BioNTech, Moderna has announced a series of encouraging vaccine trial results. preliminary results from
Pfizer and Moderna report show that the effectiveness of their respective new coronavirus vaccines is around 95 per cent, and on November 23rd AstraZeneta said its new coronavirus vaccine, developed with Oxford University, was on average 70 per cent effective and expected to rise to 90 per cent at most.
95%, 94.5%, 70%, one after another, the effective rate seems to mean that the new crown pneumonia vaccine is only a foot away from being approved for the market, the new crown vaccine market competition may be open.
the same time, people are more concerned about the price of the new crown vaccine as good news continues to come.
the world's known prices for single doses of vaccine range from Rmb20 ($3) to Rmb300 ($44).
reported that AstraZeneta's vaccine costs about $3 to $4, while Pfizer and Modelna are relatively expensive.
Based on the order agreement, Pfizer will offer the vaccine to the U.S. government for $39 for two doses or $19.50 per dose, and prices for other countries are not yet available;
, china's National Pharmaceuticals Group's vaccine could be priced at 600 yuan ($88).
both inactivated vaccines require two injections, which cost 300 yuan ($44) each.
is the single most expensive vaccine in the global vaccine market.
Is therefore hotly debated on the Internet, some netizens said that vaccines as a public health product, the unit price is set so high, it is clear that the vaccine is not as a public product, but in accordance with the principle of market supply and demand, so that enterprises profit.
For the future market pricing of the new crown vaccine, zheng Zhongwei, director of the Science and Technology Development Center of the National Health And Health Commission and head of the research team of the Joint Prevention and Control Mechanism of the State Council, participated in the "Dialogue" broadcast by CCTV Finance, revealed that the new crown vaccine belongs to the public health products, its pricing can not be based on the contradiction between supply and demand in the market, only cost as the basis for pricing, "not that enterprises can not have profits, but to cost to approve your moderate profits or reasonable profits, this is the first principle."
, deputy general manager of China National Pharmaceutical Group Co., Ltd., said that China National Pharmaceutical Group has submitted to the State Drug Administration for the listing of the new crown vaccine.
, in fact, two inactivated vaccines from China Bio, a pharmaceutical group, have been included in the emergency use of the new crown vaccine.
China's current pharmaceutical group biological vaccine research and development only a million miles long march of the last kilometer, and at this stage the new crown outbreak continues at the moment, the state for the new crown vaccine special review and approval of the increase, perhaps the new crown vaccine of the national pharmaceutical group will soon be available Batch listing, but at the same time, finally in the world has a number of vaccines have come good news and vaccine pricing decisions, the global price war on the new crown vaccine has started, the final national pharmaceutical group's new crown vaccine after the actual price is what, it remains to be seen!